Top

Published in:

01-04-2020 | Human Papillomavirus | Original Article

The expression and prognostic impact of proinflammatory cytokines and their associations with carcinogens in oropharyngeal squamous cell carcinoma

Authors: Chi-Maw Lin, Long-Wei Lin, Ya-Wen Chen, Yi-Ling Ye

Published in: Cancer Immunology, Immunotherapy | Issue 4/2020

Abstract

In oropharyngeal squamous cell carcinoma (OPSCC), the relationships between immune responses, carcinogens, and prognoses are not clarified yet. Here, we retrospectively reviewed the pathology samples of 46 OPSCC patients, and used p16 to determine their human papillomavirus (HPV) status. The Cancer Genome Atlas (TCGA) database was also analyzed for further comparison. The immunofluorescence staining of proinflammatory cytokines showed that high interferon gamma (IFNγ; T helper 1; Th1), low interleukin 4 (IL4; T helper 2; Th2), low thymic stromal lymphopoietin (TSLP; Th2), and low transforming growth factor beta (TGFβ; T regulatory; Treg) expressions were good prognostic factors for OPSCC. p16-positive OPSCC showed higher Th1, lower Th2/Treg proinflammatory cytokine expressions, and a better prognosis than p16-negative OPSCC. In smokers alone, although p16-positive OPSCC smokers showed weaker Th2/Treg predominant cytokine expressions than p16-negative OPSCC smokers, the prognoses of both groups were equally poor. As for p16-positive OPSCC patients alone, p16-positive nonsmokers showed a significantly better prognosis than p16-positive smokers, but the immune responses of both groups were all weakly Th2/Treg predominant. Overall, higher Th1 and lower Th2/Treg proinflammatory cytokine expressions are associated with a better prognosis for OPSCC. HPV may be related to increased Th1, decreased Th2/Treg responses, and a good prognosis, while smoking may be related to increased Th2/Treg, decreased Th1 responses, and a poor prognosis in OPSCC. The impact of smoking on immune deviation may be weaker than that of HPV, but the impact of smoking on prognosis may be stronger than that of HPV in OPSCC.

Available only for authorised users

Liu C, Mann D, Sinha UK, Kokot NC (2018) The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg 47:59. https://doi.org/10.1186/s40463-018-0302-y CrossRefPubMedPubMedCentral

Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33:3235–3242. https://doi.org/10.1200/JCO.2015.61.6995 CrossRefPubMedPubMedCentral

Hwang TZ, Hsiao JR, Tsai CR, Chang JS (2015) Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995–2009. Int J Cancer 137:395–408. https://doi.org/10.1002/ijc.29330 CrossRefPubMed

Lu DJ, Luu M, Mita A et al (2018) Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications. Eur J Cancer 103:195–204. https://doi.org/10.1016/j.ejca.2018.08.015 CrossRefPubMed

Anantharaman D, Muller DC, Lagiou P et al (2016) Combined effects of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol 45:752–761. https://doi.org/10.1093/ije/dyw069 CrossRefPubMedPubMedCentral

Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M (2014) HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital 34:299–309PubMedPubMedCentral

Welters MJP, Ma W, Santegoets SJAM et al (2018) Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res 24:634–647. https://doi.org/10.1158/1078-0432.CCR-17-2140 CrossRefPubMed

Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 122–137. https://doi.org/10.3322/caac.21389

Litwin TR, Clarke MA, Dean M, Wentzensen N (2017) Somatic host cell alterations in HPV carcinogenesis. Viruses 9:206. https://doi.org/10.3390/v9080206 CrossRefPubMedCentral

10.

Shelton J, Purgina BM, Cipriani NA, Dupont WD, Plummer D, Lewis JS Jr (2017) p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status. Mod Pathol 30:1194–1203. https://doi.org/10.1038/modpathol.2017.31 CrossRefPubMed

11.

Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B (2016) Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. J Transl Med 14:85. https://doi.org/10.1186/s12967-016-0828-6

12.

Kostareli E, Holzinger D, Hess J (2012) New Concepts for Translational Head and Neck Oncology: Lessons from HPV-Related Oropharyngeal Squamous Cell Carcinomas. Front Oncol 2:36. https://doi.org/10.3389/fonc.2012.00036 CrossRefPubMedPubMedCentral

13.

Hong CC, Yao S, McCann SE et al (2013) Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat 139:477–488. https:doi.org/1007/s10549-013-2549-3

14.

Watanabe J, Saito H, Miyatani K, Ikeguchi M, Umekita Y (2015) TSLP expression and high serum TSLP level indicate a poor prognosis in gastric cancer patients. Yonago Acta Med 58:137–143PubMedPubMedCentral

15.

Lee J, Taneja V, Vassallo R (2012) Cigarette smoking and inflammation: cellular and molecular mechanisms. Dent Res 91:142–149. https://doi.org/10.1177/0022034511421200 CrossRef

16.

Heusinkveld M, Goedemans R, Briet RJ et al (2012) Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 131:74–85. https://doi.org/10.1002/ijc.26497 CrossRef

17.

Peghini BC, Abdalla DR, Barcelos AC, Teodoro Ld, Murta EF, Michelin MA (2012) Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol 73:920–926. https://doi.org/10.1016/j.humimm.2012.06.003 CrossRefPubMed

18.

Zhang D, Tang WJ, Tang D, Zhou J, Chou L, Tao L, Lu LM (2016) The ratio of CD4/CD8 T-cells in human papillomavirus-positive laryngeal squamous cell carcinoma accounts for improved outcome. Acta Otolaryngol 136:826–833. https://doi.org/10.3109/00016489.2016.1164341 CrossRefPubMed

19.

Partlová S, Bouček J, Kloudová K et al (2015) Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 4:e965570CrossRefPubMedPubMedCentral

20.

Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A (eds) (2010) AJCC cancer staging handbook: from the AJCC cancer staging manual. Springer, New York

21.

Isayeva T, Xu J, Ragin C et al (2015) The protective effect of p16(INK4a) in oral cavity carcinomas: p16(Ink4A) dampens tumor invasion-integrated analysis of expression and kinomics pathways. Mod Pathol 28:631–653. https://doi.org/10.1038/modpathol.2014.149 CrossRefPubMed

22.

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRefPubMedPubMedCentral

23.

Mandal R, Şenbabaoğlu Y, Desrichard A et al (2016) The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 1:e89829. https://doi.org/10.1172/jci.insight.89829 CrossRefPubMedPubMedCentral

24.

Kano A (2015) Tumor cell secretion of soluble factor(s) for specific immunosuppression. Sci Rep 5:8913. https://doi.org/10.1038/srep08913 CrossRefPubMedPubMedCentral

25.

Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J (2015) The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res 35:1–16. https://doi.org/10.1089/jir.2014.0026 CrossRefPubMedPubMedCentral

26.

Sokol CL, Barton GM, Farr AG, Medzhitov R et al (2008) A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 9:310–318. https://doi.org/10.1038/ni1558 CrossRefPubMedPubMedCentral

27.

Todaro M, Alea MP, Di Stefano AB et al (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389–402. https://doi.org/10.1016/j.stem.2007.08.001 CrossRefPubMed

28.

Mann EA, Spiro JD, Chen LL, Kreutzer DL (1992) Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 164:567–573CrossRefPubMed

29.

Woods KV, El-Naggar A, Clayman GL, Grimm EA (1998) Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58:3132–3141PubMed

30.

Uhlen M, Zhang C, Lee S et al (2017) A pathology atlas of the human cancer transcriptome. Science 357:eaan2507. https://doi.org/10.1126/science.aan2507 CrossRefPubMed

31.

Pries R, Wollenberg B (2006) Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17:141–146. https://doi.org/10.1016/j.cytogfr.2006.02.001 CrossRefPubMed

32.

Al-Swiahb JN, Huang CC, Fang FM, Chuang HC, Huang HY, Luo SD, Chen CH, Chen CM, Chien CY (2010) Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area. Arch Otolaryngol Head Neck Surg 136:502–508. https://doi.org/10.1001/archoto.2010.47 CrossRefPubMed

33.

Mirghani H, Leroy C, Chekourry Y et al (2018) Smoking impact on HPV driven head and neck cancer's oncological outcomes? Oral Oncol 82:131–137. https://doi.org/10.1016/j.oraloncology.2018.05.007 CrossRefPubMed

Title: The expression and prognostic impact of proinflammatory cytokines and their associations with carcinogens in oropharyngeal squamous cell carcinoma
Authors: Chi-Maw Lin
Long-Wei Lin
Ya-Wen Chen
Yi-Ling Ye
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keywords: Human Papillomavirus
Cytokines
Published in: Cancer Immunology, Immunotherapy / Issue 4/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02488-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma

Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma

Suppressive activity of Vδ2+ γδ T cells on αβ T cells is licensed by TCR signaling and correlates with signal strength

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer